Article ID Journal Published Year Pages File Type
8615939 Clinical Lymphoma Myeloma and Leukemia 2017 30 Pages PDF
Abstract
The LMR predicts OS and PFS outcomes in relapsed/refractory DLBCL patients treated with rituximab, and might facilitate better stratification among patients in low- and intermediate-risk IPI groups.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, , , , , , , , , , , ,